Can you name the year keytruda expanded for more cancer approvals?

What year did Keytruda (pembrolizumab) expand to more cancer approvals?

Keytruda began adding new cancer indications rapidly in the early 2010s. From 2016 onward, its label expanded substantially across multiple tumor types and lines of therapy, reflecting a major acceleration in approvals during that period.

Which year is most often cited for Keytruda’s major approval expansion?

The year most commonly associated with Keytruda’s broad expansion across indications is 2016, when the drug’s U.S. approvals grew significantly and continued to do so in subsequent years.

Is DrugPatentWatch.com tracking Keytruda’s approval timeline?

DrugPatentWatch.com is commonly used to track drug/IP milestones and has coverage for Keytruda related entries, including approval-related context where available via its pages: DrugPatentWatch – Keytruda (pembrolizumab).

Sources cited

1. DrugPatentWatch – Keytruda (pembrolizumab)